Skip to main content
  • Endoscopic Endonasal Surgery for Cushing's Disease

    Final Number:
    1292

    Authors:
    Samuel S. Shin MD, PhD; Sue M. Challinor; Jason Ng M.D.; Srinivas Chivukula; Amir H. Faraji MD, PhD; Maria Koutourousiou MD; Eric Wang; Juan Carlos Fernandez-Miranda MD; Carl Snyderman MD; Paul A. Gardner MD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2013 Annual Meeting

    Introduction: Both initial and long term endocrinological outcomes after endoscopic endonasal surgery (EES) on Cushing’s disease patients are reported.

    Methods: Retrospective review of patients from April 2002 to October 2012 was conducted. Only the patients with follow up at least 2 months postoperatively were assessed. Patients were considered to be in initial postoperative remission from Cushing’s disease if they had symptoms of adrenal insufficiency requiring glucocorticoid replacement and a nadir cortisol = 5 mcg/dl during the first 36 hr after surgery and/or an 8 am cortisol = 5 mcg/dl. Remission was considered to be maintained during the follow up period if they had resolution of Cushing’s symptoms and met one or more of the following criteria: 1.) 8 am cortisol = 5 mcg/dl with continued requirement for glucocorticoid replacement, 2.) 8 am cortisol = 1.8 mcg/dl after 1 mg Dexamethasone, 3.) a normal 24 urine free cortisol and creatinine, and 4.) two normal late night salivary cortisol levels.

    Results: Among 47 patients with endocrinological data, 42 (89.4%) achieved remission at initial follow up, and 33 (70.2%) achieved remission at last follow up. Mean follow up time was 38.0 months (range:8 weeks-10.2 years). Complications included panhypopituitarism (n=3), hypothyroidism (n=3), growth hormone deficiency (n=1), hypogonadism (n=1), and postoperative cerebrospinal fluid leak (n=1). Nine cases had previous surgery, and 2 cases had previous radiotherapy. Three of the patients received radiotherapy after EES. Three patients were on ketoconazole at the last follow up. There were 35 cases (74.5%) with microadenomas, and 12 cases (25.5%) with macroadenomas. Remission rate at the last follow up was 71.4% (25 of 35) for microadenomas and 66.6% (8 of 12) for macroadenomas.

    Conclusions: EES offers a safe and effective treatment option for Cushing’s disease. Further analysis can guide clinicians in predicting long term endocrinological outcome after EES.

    Patient Care: This study will guide clinicians in realistic insight into the rates of disease remission and common complications for EES.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1. Describe some of the criteria for remission of Cushing's disease, 2. Describe the complication rates and types of complications after EEA for Cushing's disease

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy